RT Journal Article
T1 Association of diabetes and diabetes treatment with incidence of breast cancer.
A1 García-Esquinas, Esther
A1 Guinó, Elisabeth
A1 Castaño-Vinyals, Gemma
A1 Pérez-Gómez, Beatriz
A1 Llorca, Javier
A1 Altzibar, Jone M
A1 Peiró-Pérez, Rosana
A1 Martín, Vicente
A1 Moreno-Iribas, Concepción
A1 Tardón, Adonina
A1 Caballero, Francisco Javier
A1 Puig-Vives, Montse
A1 Guevara, Marcela
A1 Villa, Tania Fernández
A1 Salas, Dolores
A1 Amiano, Pilar
A1 Dierssen-Sotos, Trinidad
A1 Pastor-Barriuso, Roberto
A1 Sala, María
A1 Kogevinas, Manolis
A1 Aragonés, Nuria
A1 Moreno, Víctor
A1 Pollán, Marina
K1 Breast cancer
K1 Diabetes Mellitus
K1 Insulin
K1 Metformin
K1 Triple-negative breast neoplasms
AB The aim of this study was to evaluate the association of diabetes and diabetes treatment with risk of postmenopausal breast cancer. Histologically confirmed incident cases of postmenopausal breast (N = 916) cancer were recruited from 23 Spanish public hospitals. Population-based controls (N = 1094) were randomly selected from primary care center lists within the catchment areas of the participant hospitals. ORs (95 % CI) were estimated using mixed-effects logistic regression models, using the recruitment center as a random effect term. Breast tumors were classified into hormone receptor positive (ER+ or PR+), HER2+ and triple negative (TN). Diabetes was not associated with the overall risk of breast cancer (OR 1.09; 95 % CI 0.82-1.45), and it was only linked to the risk of developing TN tumors: Among 91 women with TN tumors, 18.7 % were diabetic, while the corresponding figure among controls was 9.9 % (OR 2.25; 95 % CI 1.22-4.15). Regarding treatment, results showed that insulin use was more prevalent among diabetic cases (2.5 %) as compared to diabetic controls (0.7 %); OR 2.98; 95 % CI 1.26-7.01. They also showed that, among diabetics, the risk of developing HR+/HER2- tumors decreased with longer metformin use (ORper year 0.89; 95 % CI 0.81-0.99; based on 24 cases and 43 controls). This study reinforces the need to correctly classify breast cancers when studying their association with diabetes. Given the low survival rates in women diagnosed with TN breast tumors and the potential impact of diabetes control on breast cancer prevention, more studies are needed to better characterize this association.
YR 2015
FD 2015-04-29
LK http://hdl.handle.net/10668/9783
UL http://hdl.handle.net/10668/9783
LA en
DS RISalud
RD Apr 19, 2025